newsfilter
← Latest News
Business Wire·

bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy

bluebird bio, Inc. (NASDAQ:BLUE) announced today that it has completed the first commercial cell collection for LYFGENIA (lovotibeglogene autotemcel), a one-time gene therapy for the treatment of sickle cell disease in